When do biologic drug patents expire and when will biosimilars launch?

Comprehensive patent-claim and landscape analysis of US Patent 9,914,770: Ranibizumab periplasmic inclusion-body refolding using inducible split-host expression

US Patent 9,914,770 centers on a manufacturing process for ranibizumab that uses inducible promoter-driven expression in two separate host cells, with signal-sequence routing to the periplasm, followed by harvesting periplasmic inclusion bodies, solubilization, and in vitro refolding of the light and heavy chains. The claim set is process-focused, narrow in execution details (split-hosts; periplasmic inclusion bodies; refolding), and heavily tied to specific sequence identifiers (SEQ ID NOs 1, 2, 3, 4, 5, 6) and OD targets.

This is the type of patent that can be decisive in licensing and litigation when challengers attempt to keep a product secreted periplasmically, refolded, or produced as inclusion-body-derived material in a way that still reads on the “periplasmic inclusion bodies” and “in vitro refolding” steps. It is less likely to block forms of ranibizumab made by standard secreted mammalian expression or by entirely different refolding paradigms, unless the competitor uses inducible split-host periplasmic inclusion bodies and refolds.

What does US 9,914,770 claim protect in ranibizumab manufacturing processes?

Short answer: It protects a specific ranibizumab production workflow that splits light-chain and heavy-chain expression into separate host cells, drives each chain via an inducible promoter and a periplasm-targeting signal sequence (SEQ ID NO: 5 for light, SEQ ID NO: 6 for heavy), expresses chains as periplasmic inclusion bodies, then solubilizes and refolds each chain in vitro.

Claim 1: Process spine that defines infringement risk

Claim 1 recites the following essential elements:

Two separate host cells, each transformed with a different vector:
- First host cell transformed with first vector carrying first polynucleotide:
  - encodes signal sequence SEQ ID NO: 5 operably linked to ranibizumab light chain SEQ ID NO: 2
  - placed under an inducible promoter system
- Second host cell transformed with second vector carrying second polynucleotide:
  - encodes signal sequence SEQ ID NO: 6 operably linked to ranibizumab heavy chain SEQ ID NO: 4
  - placed under an inducible promoter system
Separate culturing of each host cell in growth medium.
Expression pattern:
- light chain expressed in first host as periplasmic inclusion bodies
- heavy chain expressed in second host as periplasmic inclusion bodies
Downstream steps:
- solubilization of inclusion bodies
- in vitro refolding of the solubilized light chain and heavy chain

Critical reading: “periplasmic inclusion bodies” + “refolding in-vitro” are the two technical phrases most likely to separate a reading infringement vs non-infringement. Many ranibizumab manufacturing processes do not deliberately target periplasmic inclusion bodies as the intermediates for separate chain refolding.

Dependent claims narrow execution parameters and sequence windows

Claim 2 ties the light-chain routing specifically to signal sequence SEQ ID NO: 5 directing transport to periplasm.
Claim 3 ties heavy-chain routing specifically to signal sequence SEQ ID NO: 6.
Claim 4 adds an operational parameter: first host cultured to OD600 ~50.
Claim 5 adds another operational parameter: second host cultured to OD600 ~100.
Claim 6 constrains the first polynucleotide to nt 8 to nt 718 of SEQ ID NO: 1.
Claim 7 constrains the second polynucleotide to nt 9 to nt 770 of SEQ ID NO: 3.

Infringement implication: Independent Claim 1 can still be infringed without meeting OD and nucleotide-window limitations if those limitations appear only in dependent claims. In practice, challengers may still structure around OD triggers and use non-identical promoter/signal sequences or different inclusion-body handling.

Which claim elements are likely to be “hard” in a validity challenge under 35 USC 101/102/103?

Short answer: The most validity-sensitive components are the claim’s specificity around inducible promoter-driven periplasmic inclusion-body expression and chain-by-chain in vitro refolding. The sequence-specific constraints in dependent claims (nt windows and exact signal sequences) can help distinguish over prior art but can also invite obviousness arguments if they are routine within signal-sequence swap or known constructs.

What prior art is likely to overlap?

In the ranibizumab space, prior art that commonly overlaps with process patents includes:

microbial expression of antibody chains (light/heavy) using inducible promoters
use of periplasmic targeting signal peptides
production of inclusion bodies and refolding protocols
split expression strategies for heavy and light chains (to improve folding and reduce aggregation)

If earlier references already disclose:

periplasm targeting for each chain
induction control
inclusion bodies (even if cytoplasmic rather than periplasmic)
solubilization and in vitro refolding

then the novelty argument likely shifts to “periplasmic inclusion bodies” as an intermediate and the chain-by-chain split-host approach.

Why “periplasmic inclusion bodies” is the pivot

Many microbial antibody expression systems aim for:

secreted periplasmic soluble folding (no inclusion bodies)
cytoplasmic inclusion bodies followed by refolding

A process that explicitly directs chains to end up as periplasmic inclusion bodies is not the most typical formulation. That phrasing can be the differentiator, but it also creates a measurable factual question in litigation: what did the defendant actually produce in the periplasm?

Dependent claims as “distinguishers” vs “design-around handles”

Dependent claim 6 and 7 restrict the nucleotide range of polynucleotides. If a defendant uses different start/stop nucleotides or differing coding region boundaries while keeping the same amino acid sequences, those dependent claims may not read.
Claims 2 and 3 require exact signal sequences (SEQ ID NO: 5 and SEQ ID NO: 6). Signal peptide swaps are a straightforward design-around if still functional.
OD600 limitations are less likely to be central for validity (they are runtime parameters), but they can be central for infringement if the platform must hit those specific culture densities.

How does claim construction affect infringement: what does “separately culturing” and “periplasmic inclusion bodies” mean?

Short answer: Claim 1 demands separateness at the process level and requires that inclusion bodies are periplasmic. Claim construction is likely to focus on whether the accused process produces periplasmic aggregates/inclusion bodies versus cytoplasmic inclusion bodies or a predominantly soluble periplasmic product.

“Separately culturing” as a non-trivial limitation

If the accused process:

expresses both chains in a single host culture, even if expression is sequential, then it may avoid Claim 1.
expresses in separate vessels but in one overall cultivation system can still fall within “separately culturing,” depending on how “host cell” is treated as distinct populations.

In litigation, this is a process-documentation issue: fermentation logs, induction timing, and sampling plans.

“Periplasmic inclusion bodies” as a factual issue

“Periplasmic” implies compartment localization in Gram-negative bacteria (or analogous compartmentalization). If the defendant produces inclusion bodies after cell lysis (not necessarily periplasmic), it can be non-equivalent.

Courts typically treat “inclusion bodies” as aggregated protein structures, but the periplasmic qualifier ties to where in the cell the aggregation occurs.

What patents likely cover adjacent ranibizumab process space (and where US 9,914,770 likely fits)?

Short answer: US 9,914,770 sits in a manufacturing niche between (i) antibody chain expression and signal-sequence/periplasm targeting patents and (ii) refolding and downstream handling patents. Competitors often navigate by changing host system (mammalian vs microbial), expression localization (secreted periplasmic soluble vs inclusion bodies), or refolding workflow (single-chain refolding vs simultaneous refolding).

Likely adjacent patent clusters (based on the claim’s technical features)

Ranibizumab gene and sequence patents
- constructs encoding light and heavy chains
- signal peptide and vector design
Microbial expression patents
- inducible promoter systems for antibody chains
- split expression and co-expression strategies
Periplasm targeting and folding patents
- targeting sequences and translocation mechanics
- conditions to achieve inclusion-body vs soluble periplasmic product
Inclusion body solubilization and refolding patents
- solubilization reagents (e.g., chaotropes)
- oxidative refolding buffers
- redox couples and catalysts
Purification patents
- chromatography and polishing steps
- aggregate removal and endotoxin control

US 9,914,770 adds the combination: inducible split-host periplasmic inclusion bodies plus chain-by-chain in vitro refolding.

How strong is the patent estate for blocking generic or biosimilar-like process replication?

Short answer: As a process patent with tight technical limitations, its enforceability depends on whether rivals use a sufficiently similar microbial periplasmic inclusion-body workflow. If rivals make ranibizumab in mammalian systems or in microbial systems that do not produce periplasmic inclusion bodies, the practical blocking effect declines.

Practical enforcement pathway

To enforce, a patentee typically needs:

evidence of the competitor’s manufacturing method
expert analysis showing periplasmic localization of inclusion bodies and chain-specific in vitro refolding
documentation tying plasmids/vectors/promoters/signal sequences to SEQ ID-defined constructs

For licensors, the patent’s value increases if it covers a process step that rivals must use to achieve yield or quality targets.

Does US 9,914,770 overlap with the Orange Book exclusivity timeline for Lucentis (ranibizumab)?

Short answer: US 9,914,770 is a process patent; it does not map 1:1 to Orange Book drug-substance exclusivity (which is for approved small molecules) or to the typical biologics exclusivity framework. Ranibizumab is approved as a biologic drug (Lucentis). The regulatory exclusivity landscape in the U.S. is handled through the biologics pathway and reference products, not by Orange Book exclusivity.

Implication for timing: even if the regulatory exclusivity of a reference product ends, process patents can remain enforceable for a longer period. The process patent expiration timing matters for litigation and entry planning.

What would a Paragraph IV-style challenge analog look like for a process claim like US 9,914,770?

Short answer: For biologics-like products, challenge mechanisms differ from small-molecule Paragraph IV certifications. Still, a central tactic is to argue non-infringement by manufacturing change and/or invalidate the process claims under anticipation/obviousness.

Likely defenses in litigation

Non-infringement
- different signal peptides than SEQ ID NO: 5 and 6
- expression not routed to periplasmic inclusion bodies
- refolding performed in a different manner (e.g., refolding after extraction where “periplasmic inclusion body” is no longer the relevant intermediate, or refolding of combined chains)
- single-host co-expression instead of “separately culturing” light and heavy hosts
Invalidity
- prior art references that disclose the same combination of inducible promoter-controlled antibody chain expression, periplasm targeting, inclusion bodies, solubilization, and oxidative refolding
- obviousness based on signal peptide substitution and known refolding chemistries

Which companies are most likely practicing similar ranibizumab microbial processes?

Short answer: A reliable identification requires the assignee and the full bibliographic metadata for US 9,914,770 (inventors, assignee, priority chain, and jurisdictions). That linkage is not provided here. Without that, no accurate company mapping can be made.

What manufacturing or IP barriers could a competitor face if they want to “work around” US 9,914,770?

Short answer: The highest-friction barriers are:

ensuring light and heavy chains are not generated as periplasmic inclusion bodies in separate host cells
avoiding exact SEQ ID-defined signal sequences and nucleotide windows (for dependent claims)
changing the refolding stage such that the claim’s “refolding in-vitro the solubilized light chain and heavy chain” is not met as construed

Likely design-around levers

switch to mammalian expression (removes periplasm/inclusion-body framework)
use a single host co-expression strategy
shift to soluble periplasmic folding (avoid inclusion bodies)
use different signal peptides and/or promoters
adjust polynucleotide boundaries to avoid specific nt windows
refold using alternative workflows that are materially different from the claimed “solubilized light chain and heavy chain” in vitro pairing step

Timeline: when does US 9,914,770 typically expire, and what matters most for market entry planning?

Short answer: Expiration depends on the patent’s filing date and any adjustments for prosecution delays; those bibliographic facts are not supplied here, so an exact date cannot be stated.

What matters operationally for business planning

patent expiration plus any enforceable term adjustments
whether there are continuation applications impacting claim scope
whether litigation stays or injunctions change the effective entry window
interaction with any other process or purification patents in the same family or related families

Key claim-by-claim risk map for an accused ranibizumab process

Claim	What it requires (high-level)	Main infringement pressure point	Typical work-around
1	Split-host, inducible promoters; signal-sequence driven light/heavy; periplasmic inclusion bodies; solubilize; in vitro refold	Demonstrating periplasmic inclusion bodies and the specific split-host/refolding workflow	Use soluble periplasmic expression or cytoplasmic inclusion bodies; switch host/co-expression; alter refolding workflow
2	Light uses signal sequence SEQ ID NO: 5 and periplasm routing	Match of the signal sequence identity/function	Change signal peptide
3	Heavy uses signal sequence SEQ ID NO: 6 and periplasm routing	Match of the signal sequence identity/function	Change signal peptide
4	Light culture to OD600 ~50	Culture conditions	Change induction timing/bioreactor conditions (if still achieving yield)
5	Heavy culture to OD600 ~100	Culture conditions	Change induction timing/bioreactor conditions
6	Light polynucleotide nt 8 to nt 718 of SEQ ID NO: 1	Nucleotide boundaries	Redesign coding region boundaries while retaining protein sequence
7	Heavy polynucleotide nt 9 to nt 770 of SEQ ID NO: 3	Nucleotide boundaries	Redesign coding region boundaries while retaining protein sequence

Key Takeaways

US 9,914,770 is a ranibizumab manufacturing process patent anchored on inducible split-host expression, signal peptide routing to periplasm, periplasmic inclusion bodies, and in vitro refolding from solubilized inclusion bodies.
The strongest infringement hooks are the combination of (i) periplasmic inclusion bodies and (ii) chain-specific in vitro refolding under a split-host scheme.
Dependent claims add sequence and process constraints that can be used for non-infringement arguments by changing signal peptides, promoter/vector elements, nucleotide boundaries, or OD targets.
Practical enforceability depends on the opponent’s actual manufacturing intermediate characterization (periplasmic inclusion bodies) and the process documentation for vector design and refolding steps.

FAQs

What does “periplasmic inclusion bodies” mean for antibody process infringement in U.S. courts?
Can a competitor avoid US 9,914,770 by expressing both ranibizumab chains in one host cell?
Do dependent claims with OD600 limits (claims 4 and 5) matter if the process never meets those culture densities?
If a competitor uses different signal peptides but produces periplasmic inclusion bodies, does that defeat infringement?
How do process patents like US 9,914,770 affect biologics-like entry even after regulatory exclusivity ends?

References

35 U.S.C. § 101.
35 U.S.C. § 102.
35 U.S.C. § 103.
35 U.S.C. § 271.

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Genentech, Inc.	LUCENTIS	ranibizumab	Injection	125156	June 30, 2006	⤷ Start Trial	2034-04-28
Genentech, Inc.	LUCENTIS	ranibizumab	Injection	125156	August 10, 2012	⤷ Start Trial	2034-04-28
Genentech, Inc.	LUCENTIS	ranibizumab	Injection	125156	October 13, 2016	⤷ Start Trial	2034-04-28
Genentech, Inc.	LUCENTIS	ranibizumab	Injection	125156	March 20, 2018	⤷ Start Trial	2034-04-28
>Applicant	>Tradename	>Biologic Ingredient	>Dosage Form	>BLA	>Approval Date	>Patent No.	>Expiredate

Country	Patent Number	Estimated Expiration
South Africa	201508706	⤷ Start Trial
World Intellectual Property Organization (WIPO)	2014178078	⤷ Start Trial
United States of America	2016289314	⤷ Start Trial
Russian Federation	2646098	⤷ Start Trial
Russian Federation	2015148746	⤷ Start Trial
>Country	>Patent Number	>Estimated Expiration

Patent: 9,914,770

Summary for Patent: 9,914,770